Results 91 to 100 of about 1,279,543 (154)

GLP-1 Receptor Agonists In Diabetes And Weight Management

GLP-1 receptor agonists are highly effective in lowering blood sugar levels in type 2 diabetes without causing hypoglycemia and have demonstrated cardiovascular benefits, particularly for patients with ASCVD.
Tran, Nguyen An Khe
core  

Molecular determinants of amylin receptor agonism

, 2017
Amylin is a 37 amino-acid neuroendocrine peptide hormone produced in the pancreatic β-cells alongside insulin. Food ingestion stimulates the release of both amylin and insulin for the swift restoration of blood-glucose homeostasis.
Bower, Rebekah
core  

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

, 2015
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique
Lalita Prasad-Reddy, Diana Isaacs
core   +1 more source

The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats. [PDF]

Acta Neuropsychiatr
Aranäs C, Edvardsson CE, Zentveld L, Vallöf D, Witley S, Tufvesson-Alm M, Shevchouk OT, Vestlund J, Jerlhag E.   +8 more
europepmc   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. [PDF]

Diabetes Obes Metab
Alhazmi A, le Roux CW.
europepmc   +1 more source

Emerging role of GLP-1 receptor agonists in the treatment of obesity

, 2010
Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity
Lisa M Neff, Robert F Kushner
core  

Peptide-based therapeutics targeting GPCRs: recent applications in the treatment of metabolic disorders. [PDF]

Front Pharmacol
Di Martino S, De Rosa M.
europepmc   +1 more source

For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better? [PDF]

Biology (Basel)
Giang C, Meng J, Mohammad MA, Liu Z, Wu X, Zhu Y.   +5 more
europepmc   +1 more source

Amyloidogenic amylin signaling links diabetes to dementia pathogenesis. [PDF]

Trends Pharmacol Sci
Despa F, Lashley T.
europepmc   +1 more source

Amylin: A Multi-Functional Pancreatic Hormone-A Review. [PDF]

Diabetes Obes Metab
Le Foll C, Lutz TA.
europepmc   +1 more source